stockrow
Saturday 7 November 2026
Export KYTX’s income statement to Excel — free account
Kyverna Therapeutics, Inc.
KYTX Healthcare Biotechnology
Kyverna Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $7.0 million.
- EPS
- +35.1%
- Free cash flow
- −27.1%
- Total debt
- +95,603.8%
Quarter to June 2026, against a year earlier
4.85
0.24
+5.21%
Follow KYTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 7 | — | — | — | — | — | — | 17 | 71 | +311.0% | |
| Gross margin, % | — | — | — | — | — | — | 100.00 | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (29) | (60) | (127) | (161) | (153) | +77.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | (411.29) | 0.00 | 0.00 | 0.00 | 0.00 | +411.3 pt | ||||||
| Net income | — | — | — | — | — | — | (29) | (60) | (127) | (161) | (153) | +77.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 15.42 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (63.43) | (89.61) | (3.33) | (3.64) | (2.94) | (61.4%) | ||||||
| Cash flow | — | — | — | — | — | — | (79.28) | (77.76) | (2.98) | (3.47) | (2.61) | (64.7%) | ||||||
| Capex | — | — | — | — | — | — | (1.69) | (0.92) | (0.06) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (80.97) | (78.68) | (3.04) | (3.47) | (2.61) | (65.0%) | ||||||
| Book value | — | — | — | — | — | — | (162.45) | (194.95) | 6.95 | 5.25 | 2.72 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 1 | 38 | 44 | 52 | +359.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | 0.00 | — | — | — | 1.78 | — | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | 0.69 | — | — | — | (0.76) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (36) | (52) | (114) | (154) | (159) | +62.1% | |||||
| Capex | — | — | — | — | — | — | (1) | (1) | (2) | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (37) | (53) | (116) | (154) | (159) | +60.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 41 | 41 | 257 | 246 | 184 | +81.4% | |||||
| Net debt | — | — | — | — | — | — | (50) | (57) | (286) | (255) | (175) | +71.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (74) | (131) | 267 | 232 | 166 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (84.95) | (67.12) | (53.91) | (68.40) | (53.9) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 58.78 | (188.59) | (64.67) | (87.24) | (64.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 84 | 96 | 112 | 130 | — | +15.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.08 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022
Kyverna Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals, Inc. | $293.6M | — (loss-making) | — (loss-making) | −21.60% (below 0%: shrinking) | n/m | −157.51% (below 0%: shrinking) | 100.00% | (120.04%) | Compare |
| SCTX Scribe Therapeutics Inc. | $293.1M | — | — | — | n/m | — | 100.00% | (489.83%) | Compare |
| AGEN Agenus Inc. | $290.8M | 10.7× | 27.7× | +4.14% (above 0%: growing) | −99.00% (below 0%: shrinking) | −37.06% (below 0%: shrinking) | 100.00% | 36.23% | Compare |
| KYTX Kyverna Therapeutics, Inc. | $285.1M | — (loss-making) | — (loss-making) | — | n/m | −27.06% (below 0%: shrinking) | — | 0.00% | |
| PRLD Prelude Therapeutics Incorporated | $283.7M | — (loss-making) | — (loss-making) | +42.60% (above 0%: growing) | n/m | +40.32% (above 0%: growing) | 100.00% | (270.93%) | Compare |
| FULC Fulcrum Therapeutics, Inc. | $280.8M | — (loss-making) | — (loss-making) | +27,018.64% (above 0%: growing) | n/m | −13.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| OCGN Ocugen, Inc. | $276.9M | — (loss-making) | — (loss-making) | +11.36% (above 0%: growing) | n/m | −22.15% (below 0%: shrinking) | 100.00% | (909.94%) | Compare |
| DTIL Precision BioSciences, Inc. | $275.7M | — (loss-making) | — (loss-making) | +37,272.41% (above 0%: growing) | n/m | −0.52% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NAUT Nautilus Biotechnology, Inc. | $273.9M | — (loss-making) | — | — | n/m | −28.59% (below 0%: shrinking) | 89.74% | (7,152.56%) | Compare |
| Median of peers | $282.2M | — | — | +26.98% | — | −22.15% | 100.00% | (195.48%) |
Pay and ownership Proxy statement filed 13 April 2026
Ownership
Directors and executive officers, together
17.60%
Entities affiliated with Vida Ventures, LLC
7.90%
Entities affiliated with Westlake BioPartners Fund I, L.P.
7.70%
Beth Seidenberg, M.D.
7.70%
Fred E. Cohen, M.D.
7.50%
Gilead Sciences, Inc.
6.80%
Entities affiliated with Northpond Ventures III, LP
5.70%
Bain Capital Life Sciences Opportunities III, LP
5.10%
Entities affiliated with GordonMD Global Investments GP LLC
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement